Skip to main content

Durysta Disease Interactions

There are 3 disease interactions with Durysta (bimatoprost ophthalmic).

Moderate

Bimatoprost (applies to Durysta) renal/liver disease

Moderate Potential Hazard, Low plausibility. Applicable conditions: Renal Dysfunction

Topically applied bimatoprost is systemically absorbed, then rapidly metabolized by the liver and eliminated by the kidney. Bimatoprost has not been adequately studied in the treatment of patients with impaired renal and/or hepatic function. Therapy with bimatoprost ophthalmic solution should be administered cautiously in such patients.

References

  1. (2001) "Product Information. Lumigan (bimatoprost ophthalmic)." Allergan Inc
  2. (2009) "Product Information. Latisse (bimatoprost topical ophthalmic)." Allergan Inc
Moderate

Ophthalmic PG analogues (applies to Durysta) macular edema

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Aphakia, Pseudophakia, Retinal Disorder

Macular edema, including cystoid macular edema, has been reported during treatment with ophthalmic prostaglandin analogues. Most cases occurred in patients with aphakia, pseudophakia with a torn posterior lens capsule, or known risk factors for macular edema (e.g., posterior uveitis, certain retinal disorders). Therapy with ophthalmic prostaglandin analogues should be administered cautiously in these patients.

References

  1. (2001) "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn
  2. (2001) "Product Information. Lumigan (bimatoprost ophthalmic)." Allergan Inc
  3. (2001) "Product Information. Travatan (travoprost ophthalmic)." Alcon Laboratories Inc
  4. (2009) "Product Information. Latisse (bimatoprost topical ophthalmic)." Allergan Inc
View all 4 references
Moderate

Ophthalmic PG analogues (applies to Durysta) uveitis

Moderate Potential Hazard, Moderate plausibility.

Bimatoprost, latanoprost, and travoprost are synthetic prostaglandin analogues. Theoretically, these agents may mimic endogenous prostaglandins and mediate ocular inflammatory responses. In clinical trials, uveitis and iritis have been reported rarely. Therapy with ophthalmic prostaglandin analogues should be administered cautiously in patients with active intraocular inflammation.

References

  1. (2001) "Product Information. Xalatan (latanoprost ophthalmic)." Pharmacia and Upjohn
  2. (2001) "Product Information. Lumigan (bimatoprost ophthalmic)." Allergan Inc
  3. (2001) "Product Information. Travatan (travoprost ophthalmic)." Alcon Laboratories Inc

Durysta drug interactions

There are 7 drug interactions with Durysta (bimatoprost ophthalmic).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer